Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CEL | P19835 | 4/20 | 0.37 |
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19793865 | 1.00 | MAPT (0.45) | MAPTCELELANEHCAR2CYP1A2 | |
| SCHEMBL19793857 | 0.99 | MAPT (0.43) | MAPTCELELANEHCAR2CYP1A2 | |
| SCHEMBL19793868 | 0.98 | MAPT (0.45) | MAPTCELELANEHCAR2CYP1A2 | |
| SCHEMBL19793853 | 0.97 | MAPT (0.40) | MAPTCELELANEHCAR2CYP1A2 | |
| SCHEMBL19793871 | 0.96 | MAPT (0.45) | MAPTCELELANEHCAR2CNR2 | |
| SCHEMBL19793856 | 0.96 | MAPT (0.40) | MAPTCELELANEHCAR2CYP1A2 | |
| SCHEMBL19793858 | 0.96 | MAPT (0.45) | MAPTCELELANEHCAR2CNR2 | |
| SCHEMBL19793875 | 0.95 | MAPT (0.44) | MAPTCELELANEHCAR2CNR2 | |
| SCHEMBL19793867 | 0.94 | MAPT (0.43) | MAPTCELELANEHCAR2CNR2 | |
| SCHEMBL19793852 | 0.94 | MAPT (0.37) | MAPTCELHCAR2CYP1A2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428273-B2 | Liquid crystal compound having benzopyran skeleton, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2019-10-01 | — | — | US | disclosed |
| US-20180022998-A1 | LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| US-20180022998-A1 | LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428273-B2 | Liquid crystal compound having benzopyran skeleton, liquid crystal composition, and liquid crystal display device | PIEZO1, PYCARD, NLRP1 | MAPT 161/4885CEL 361/4885ELANE 2653/4885 |
| US-20180022998-A1 | LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | PIEZO1, NLRP1, PYCARD | MAPT 175/4885CEL 337/4885ELANE 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.